TWD 38.75
(-1.77%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 158.62 Million TWD | -12.03% |
2022 | 180.31 Million TWD | 14.35% |
2021 | 157.69 Million TWD | 8.99% |
2020 | 144.68 Million TWD | -9.04% |
2019 | 159.07 Million TWD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q3 | 39.29 Million TWD | -2.03% |
2024 Q1 | 40.77 Million TWD | 84.11% |
2024 Q2 | 40.1 Million TWD | -1.65% |
2023 Q3 | 38.93 Million TWD | -1.0% |
2023 Q4 | 22.14 Million TWD | -43.11% |
2023 Q2 | 39.32 Million TWD | -2.36% |
2023 Q1 | 40.27 Million TWD | -19.08% |
2022 Q4 | 49.77 Million TWD | 0.0% |
2022 FY | 180.31 Million TWD | 14.35% |
2021 FY | 157.69 Million TWD | 8.99% |
2020 FY | 144.68 Million TWD | -9.04% |
2019 FY | 159.07 Million TWD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
BIONET Corp. | 553.58 Million TWD | 71.347% |
Genetics Generation Advancement Corp. | 218.25 Million TWD | 27.323% |
Welgene Biotech Co.,Ltd. | 123.97 Million TWD | -27.946% |
Puriblood Medical Co., Ltd. | 56.92 Million TWD | -178.644% |
TFBS Bioscience Inc. | 77.82 Million TWD | -103.807% |